[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581690":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":37,"locations":43,"responsibleParty":63,"collaborators":25,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":25,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University of Calgary","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: Pharmacogenetic (PGx)-Guided","EXPERIMENTAL","Participants and their physician will receive a one-time prescribing report after completing baseline for selective serotonin reuptake inhibitors with dosing information based on CYP2B6, CYP2C19, and CYP2D6 genotype data, and clinical practice guidelines for fluoxetine as there are no pharmacogenetic guidelines for this medication.",[13],"Other: Pharmacogenetic-guided dosing",{"label":15,"type":16,"description":17,"interventionNames":18},"Current Prescribing Guidelines\u002FRecommendations","ACTIVE_COMPARATOR","Participants and their physician will receive a one-time prescribing report after completing baseline for selective serotonin reuptake inhibitors based on current prescribing guidelines\u002Frecommendations.",[19],"Other: Current prescribing guidelines\u002Frecommendations",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Pharmacogenetic-guided dosing","SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Current prescribing guidelines\u002Frecommendations","SSRI dosing based on current prescribing guidelines\u002Frecommendations",[15],[31,34],{"name":32,"affiliation":5,"role":33},"Chad Bousman, PhD","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":36,"role":33},"Amanda Newton, PhD","University of Alberta",[38],{"name":39,"role":40,"phone":41,"phoneExt":25,"email":42},"Madison Heintz, MSW","CONTACT","587-223-3154","gap@ucalgary.ca",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Calgary","Alberta","T2N 4N1","Canada","CA",{"type":52,"coordinates":53},"Point",[54,55],-114.08529,51.05011,{"lat":55,"lon":54},[58,61,62],{"name":59,"role":40,"phone":60,"phoneExt":25,"email":42},"Meagan Shields, BSc., MSc.","403-210-6353",{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"name":35,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":33,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Chad Bousman","Professor","100581690","pharmacogenetic-guided-antidepressant-prescribing-in-adolescents-with-anxiety-and-depression-100581690",false,"NCT06853587","Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression","PGx-GAP","Inclusion Criteria:\n\n* Age 12-17\n* Depression and\u002For anxiety as the primary concern, confirmed by the treating physician\n* Intention to start a new SSRI\n* English fluency\n\nExclusion Criteria:\n\n* Co-occurring obsessive compulsive disorder, psychosis, bipolar disorder, eating disorder, autism spectrum disorder, fetal alcohol spectrum disorder, or intellectual disability\n* History of non-response to 3 or more SSRI medications as confirmed by the treating physician\n* Brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate\u002Fchange brain stimulation during study participation\n* History of liver or hematopoietic cell transplant\n* History of CYP2B6, CYP2C19, or CYP2D6 testing","ALL","12 Years","17 Years",{"count":77,"type":78},228,"ESTIMATED","INTERVENTIONAL",[81],"NA","This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=228) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression and\u002For anxiety will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or current prescribing guidelines\u002Frecommendations guided therapy (control intervention).",[84],"Anxiety and Depression",[86,87,88,89,90,91],"depression","anxiety","adolescence","SSRI","antidepressant","pharmacogenetics","2026-06-17",{"date":94,"type":95},"2026-06-22","ACTUAL",{"date":97,"type":95},"2025-02-11",{"date":99,"type":78},"2027-12",{"name":5,"class":6},1]